Core Insights - Sarepta Therapeutics Inc. shares dropped 37% following disappointing trial results for two treatments aimed at Duchenne muscular dystrophy (DMD) [1] Company Summary - The biotechnology company reported unsatisfactory outcomes from clinical trials, which significantly impacted investor confidence and stock performance [1] Industry Context - The results highlight ongoing challenges in the biotechnology sector, particularly in developing effective treatments for rare diseases like DMD [1]